Although hormonal therapy is highly efficacious, alternative therapeutic approaches for ER+ breast cancer subtypes must be explored as the cancer cells exhibit endocrine therapy resistance and epigenomic reprogramming. This evidence concerns the gene ESR1 and breast cancer.